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Aims Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion therapy in ST-elevation myocardial
infarction (STEMI). We conducted this study to evaluate the contemporary status on the use and type of reperfusion
therapy in patients admitted with STEMI in the European Society of Cardiology (ESC) member countries.
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Methods
and results
A cross-sectional descriptive study based on aggregated country-level data on the use of reperfusion therapy in patients
admitted with STEMI during2010 or 2011. Thirty-seven ESC countries wereable to providedata from existingnational or
regional registries. In countries where no such registries exist, data were based on best expert estimates. Data were col-
lected on the use of STEMI reperfusion treatment and mortality, the numbers of cardiologists, and the availability of PPCI
facilities ineachcountry. Our survey providesabrief data summaryof thedegreeof variation in reperfusion therapyacross
Europe. The number of PPCI procedures varied between countries, ranging from 23 to 884 per million inhabitants.
Primary percutaneous coronary intervention and thrombolysis were the dominant reperfusion strategy in 33 and 4 coun-
tries, respectively. The mean population served by a single PPCI centre with a 24-h service 7 days a week ranged from
31 300 inhabitants per centre to 6 533 000 inhabitants per centre. Twenty-seven of the total 37 countries participated
in a former survey from 2007, and major increases in PPCI utilization were observed in 13 of these countries.
Conclusion Large variations in reperfusion treatment are still present across Europe. Countries in Eastern and Southern Europe
reported that a substantial number of STEMI patients are not receiving any reperfusion therapy. Implementation of
the best reperfusion therapy as recommended in the guidelines should be encouraged.
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Introduction
Guidelines from the European Society of Cardiology (ESC) call for
timely coronary artery reperfusion in patients with ST-elevation
myocardial infarction (STEMI) and stress that, if available, primary
percutaneous coronary intervention (PPCI) is the preferred strat-
egy.1 Despite its advantages, PPCI is not universally implemented
and thrombolysis is still used in many patients. Furthermore, a large
group of patients presenting with STEMI are not receiving any reper-
fusion therapy.2– 4 The reasons for these differences in the use of
reperfusion therapy in the ESC countries are poorly understood.
However, prior studies suggest that clinical factors, financial concerns
as well as obstacles, and organizational difficulties are key factors.5,6
To overcome these types of barriers, systems of care have been
developed such as establishment of regional STEMI networks with
very encouraging results.7,8
This descriptive study reports the current use of reperfusion treat-
ment in 37 ESC countries. The study is a follow-up of the survey con-
ducted in 2007 including more countries. A total of 27 countries
participated in both surveys. The present survey includes the same
study variables collected in the former survey, whereas the data
sources vary.4
Methods
This was a cross-sectional descriptive study based on aggregated survey
data from 36 ESC member countries and 1 affiliated ESC country in
2010/2011. The 55 National Societies within the ESC were kindly
asked to provide country-level data. Positive replies were received
from 37 ESC countries, including one affiliated ESC country. The collec-
tion of data was a substantial task, and consequently, one representative/
contact person from each country is listed as a co-author of this report.
The study consisted of self-administered questionnaires completed by
the national contact persons providing information on the following
items: the number of STEMI patients per 1 000 000 inhabitants treated
with (i) PPCI, (ii) thrombolysis, and (iii) patients receiving no reperfusion
therapy. We also collected data on mortality assessed as overall
in-hospital mortality according to the type of reperfusion therapy.
Furthermore, we gained data on information on existing national
STEMI or PCI registries and on the organization of treatment manage-
ment (number of PPCI centres per 1 000 000 inhabitants and number
of cardiologists per 1 000 000 inhabitants). Twenty-seven of the 37 coun-
tries were also participating in the survey conducted in 2007/2008, and
data on the utilization of PPCI were available for comparison. Numbers
of patients treated with thrombolysis and the numbers of patients not
receiving reperfusion therapy were in 2007/2008 given as percentage
and can therefore not be compared.
Since most of the countries in Europe at present do not have national
or regional registries on PPCI or STEMI, we allowed the national contact
persons to report their best estimates. The following country data were
based solemnly on contact person’s estimates: Azerbaijan, Bosnia
and Herzegovina, Georgia, and the Netherlands. Only nine countries
(Austria, Belgium, Denmark, Germany, Iceland, Italy, Poland, Sweden,
and UK) have national registries covering the entire STEMI population
with mandatory registration and continued data validation (Table 1).
After conduction of the survey in 2007/2008, a substantial number of
countries have taken the initiative to establish more permanent data
registries with national coverage. Examples are Romania and Bulgaria
with fairly new established registries covering 70% of the STEMI popula-
tion. The completeness of STEMI capturing during the time period in the
various registries ranged from 14.5% coverage in Greece to 100% cover-
age in some countries, i.e. Denmark, Sweden, and the UK. In some coun-
tries, e.g. France, Egypt, Greece, Ireland, and Slovakia, data were based on
surveys and snapshots. A full description of the data sources are given in
Table 1. Since mortality data are highly dependent on sound registration,
we choose to include only mortality data from countries where a national
STEMI registry and a national PCI registry exist (Table 3).
Data analysis
We provided descriptive analysis of the type of reperfusion utilization in
2010/2011 for each country. For the 27 countries participating in both
surveys, we moreover included comparative numbers on the utilization
of PPCI. The use of reperfusion therapy is presented as numbers per
1 000 000 inhabitants. Numbers of available cardiologists are presented
per 1 000 000 inhabitants and numbers of available PPCI hospitals per
mean population. Correlation between the number of cardiologists per
1 000 000 inhabitants and the number of performed PPCI per million
inhabitants was done using Spearmans’ rank correlation test. Mortality
data are presented as percentages.
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Table 1 Description of country data sources
Country Data
from
the
year
Existing
national PCI
registry
Existing regional PCI
registry
Existing
national
STEMI
registry
Existing
regional
STEMI
registry
Expert
estimates
only
Completeness of STEMI
capturing per period/
percentage of STEMI
population covered by the
registry
Comments to data content
Austriaa 2011 Austrian PCI
registry
PCI registry
Wilhelminen
Hospital Vienna
No Vienna, STEMI
registry
90% (estimate)
Azerbaijan 2011 x
Belgiuma 2011 Belgian PCI
registry
No Belgian STEMI
registry
No STEMI database 50%
PCI database 100%
Bosnia and
Herzegovina
2011 x
Bulgaria 2011 Started
November
2011
No Started
November
2012
No 70% Data from various sources: The National Health
Insurance Fund, National Social Security
Institute, National Center of Public Health and
Analyses as well as from the National PCI
centres
Croatiaa 2011 No Yes Yes Yes .90% Croatian Institute for Public Health and regional
and in-hospital ACS/STEMI/PPCI registries
Cyprus 2009 No No No No NA Data for STEMI were based on CYPACS Study/
Registry in 2009. Data for PPCI were based on
unpublished data for the year 2011, presented
at the Cyprus Society of Cardiology National
Congress, year 2012
Czech Republic 2011 Yes Yes No Yes 92% Register + approximation based on current and
older data
Denmark 2010 The Danish
Heart
Registry
The Western Denmark
Heart Registry, PATS
(The Eastern
Denmark Heart
Registry
The Danish
National
Patient
Registry
The Danish
National
Patient
Registry
100%
Egypt 2011 Yes Yes 36%, 31 million people Based on the 1st Phase of Egyptian Stent For Life
registry (9 months). Four areas only: Cairo,
Alexandria,Delta, andCanal. Fourteencath labs
Finland 2011 No Yes No Yes—some Near 100% PCI data based on registry data, STEMI data based
on expert estimates
Continued
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Table 1 Continued
Country Data
from
the
year
Existing
national PCI
registry
Existing regional PCI
registry
Existing
national
STEMI
registry
Existing
regional
STEMI
registry
Expert
estimates
only
Completeness of STEMI
capturing per period/
percentage of STEMI
population covered by the
registry
Comments to data content
Francea 2011 ONACI RICO, Cardio ARIF,
ORBI, Center
registry, PACCA
registry, Alpine
registry
No RICO, Cardio
ARIF, ORBI,
Center
Registry,
PACCA
registry,
Alpine
registry
35% Based on the FAST-MI survey data
Georgia 2011 No No No No x Numbers are based on data from only five PCI
centres. (insured patients only)
Germany 2011 No Yes
Berlin, Essen,
Hildesheim/
Association of
Clinical Cardiology
Directors (ALKK)
Ludwigshafen/ALKK
No Yes Activity numbers are based on BQS:
AQUA-Institut, data collection is mandatory.
Staff numbers are based on Bruckenberger, the
German Heart Statistics 2011
Greece 2011 No Yes No No 14.5 % Data based on Stent for Life Registry, Hellenic PCI
Registry
Hungary 2011 Yes Yes Partially Yes 50%
Snapshot survey (2011) 92%
Iceland 2011 Yes Yes Yes Yes PCI 100% SWEDEHEART. Data on the use of thrombolysis
are based on expert estimatesSTEMI 95%
Ireland 2011 No No No No NA (1) Heartbeat voluntary STEMI database of 20
participating hospitals (July 2011 to June 2012)
covering 58% of the population (in
conjunction with CHAIR regional registry and
HIPE national hospital administrative system)
(2) Medical Council (registering body) for the
number of cardiologists
Israel 2010 Yes Record PCI 1—ACSIS
ACS
1 Recode PCI Data are extrapolated (i.e. six
times) from a 2-month
national ACS surveillance
ISRAEL ACSIS 2010 National ACS Registry
Italy 2010 Yes Yes Yes Yes BLITZ 1 (2 weeks snapshot in
.90% Italian CCUs;
BLITZ-4 a weeks snapshot
representative of
approximately one-fifth of
total CCUs)
Data are based on GISE databasea, data on
thrombolysis, and no reperfusion are based on
BLIZ-4
S.D
.K
ristensen
etal.
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Latviaa 2011 No Yes Yes No 90%
Marcedoniaa 2011 Yes Yes Yes Yes 85% Based on national registry
Netherlands 2011 Yes Yes No No Yes Based on expert estimate and extrapolation of
data from 18 interventional centres
Portugal 2011 2 different No 2 different No NA
Polanda 2011 Yes Yes Yes Yes PL-ACS registry, national PCI database,
thrombolysis, and number of patients not
receiving any reperfusion are based on expert
opinion
Romaniaa 2011 Yes No Yes No 70% Based on RO-STEMI
San Marino 2011 No No Yes No 100%
Saudi Arabia 2011 Yes No Yes Yes Representative snapshot,
particularly of the
governmental tertiary care
hospitals
(1) National PCI Registry (CARES)
(2) National ACS Registry (SPACE)
(3) Regional ACS Registries (Gulf RACE-1 and
Gulf RACE-2)
(4) National experts estimates
Serbiaa 2011 No Yes Yes No National registry for ACS
covers all hospitalized ACS
patients in Serbia
Clinical Centre of Serbia PPCI registry, National
registry for ACS, Annual cath-lab reports of all
PCI centres
Slovakia 2011 No No Yes Yes 80–90% Based on a 2-month snapshot covering 90% of
hospitals. The results are multiplied by six to get
1-year data.
Slovenia 2011 No In each CL No In each CL 100%
Spain 2010 Yes Yes Yes Yes 28.73% based on Regional
STEMI Networks Registry
Spanish Society of Cardiology, PCI Registry.
Prevalence of STEMI vs. non-STEMI based on
MASCARA registry. Thrombolysis was based
on the Spanish Society of Cardiology, PCI
Registry (6% ACS non-classifiable)
Swedena 2011 Yes No Yes No 100% Swedeheart, HIA
Switzerlanda 2011 No, a
nationwide
annual
survey of
PCI
No AMIS plus AMIS plus ca. 30% Information based on voluntarily hospitals
participation in AMIS Plus Registry
Turkey 2011 No No No No Data sent from 25 pilot cities of SFL initiative
UKa 2010
and
2011
Yes Yes Yes Yes 100% BCIS PPCI data for all UK 2011. MINAP data for
2010 England and Wales—thrombolysisMINAP
BCIS
Ukraine 2011 Yes (covering
just 75%)
No No No NA Information based on data from ‘Ukrainian
Register of Percutaneous Coronary
Interventions’, reporting the Ministry of Health.
Personal communication with PCI centres
CCU, Critical Care Unit; CL, County Level; HIA, Healt Impact Assesment.
aBased on the same data sources as the survey published in 20104.
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Results
Utilization of primary percutaneous
coronary intervention in2007and2010/2011
Figures 1 and 4 show the use of PPCI in the participating 37 countries.
Primary percutaneous coronary intervention utilization varied con-
siderable between countries with a range from 23 to 884 PPCI
procedures per 1 000 000 inhabitants (Figure 1). Countries with the
highest utilization of PPCI per 1 000 000 were Austria, Bulgaria,
Germany, the Netherlands, and Poland. Azerbaijan, Cyprus, Egypt,
Georgia, Saudi Arabia, and Ukraine had the lowest utilization
(Figure 1). Most countries had PPCI rates around 400–600 proce-
dures per 1 000 000 inhabitants (Figures 1 and 4). Twenty-seven of
the total 37 countries participated in the former survey. Major
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Number of available cardiologists, hospitals capable of performing acute and non-acute percutaneous coronary
intervention, and population per centre
Country Country
population 1
January 2011
Mean number of
board-certified cardiologists
per million population
Numbers of
PCI hospitals
Numbers of PCI
hospitals with 24/7
PPCI service
Mean population
per PPCI centre
(24/7 service)
Austria 8 404 252 35.7 36 14a 600 300
Azerbaijan 9 111 078 0.22 7 4 2 280 000
Belgium 10 951 665 73.0 36 36 304 000
Bosnia and Herzegovina 3 843 183 21.1 5 2 1 922 000
Bulgaria 7 504 868 86.6 33 33 227 500
Croatia 4 412 137 NA 12 9 490 300
Cyprus 804 435 165 4 0 NA
Czech Republic 10 513 209 71.3 22 22 478 000
Denmark 5 560 628 58.4 7 5 1,112,000
Egypta 82 079 632 25.8 93 31 2,654,800a
Finland 5 375 276 24.7 23 3 1 792 000
Franceb 65 821 885 9.1 210 210b 313 000a
Georgiab 4 469 250 33.6 9 4 1 117 300a
Germany 81 780 000 36.0 521 NA NA
Greeceb 10 787 690 243.8 49 15 754 000
Hungaryb 9 985 722 40.0 17 17 587 400
Iceland 318 452 78.5 1 1 318 500
Ireland 4 480 858 22.1 16 4 1 120 200
Italyb 60 626 442 NA 255 211 287 300
Israel 7 873 052 72.2 24 22 311 400
Latvia 2 229 641 65.0 4 2 1 114 800
Macedonia 2 077 328 17.8 4 4 519 300
The Netherlands 16 696 000 55.7 31 22 759 000
Portugal 10 636 979 54.5 29 21 506 500
Poland 38 200 037 50.2 137 114 335 100
Romania 19 042 936 57.7 22 12 1 586 911
San Marino 31 269 191.9 1 1 31 300
Saudi Arabia 26 316 704 11.5 30 4 6 533 000
Serbia 7 276 195 NA 11 5 1 455 200
Slovakia 5 404 322 78.6 6 4 1 351 000
Slovenia 2 050 189 11.2 5 2 1 025 094
Spain 46 152 ‘926 46.9 126 78 591 700
Sweden 9 415 570 78. 29 12 784 600
Switzerland 7 870 134 12.6 32 26 302 700
Turkeyb 14 283 013 13.0 27 15 952 200
UK 63 141 700 NA 117 57 1 107 749
Ukraine 45 134 707 55.5 37 11 4 103 200
aIn Austria, further 14 centres perform PPCI in STEMI patients for 1 up to 3 days 24 h within networks that offer a rotational system of open catheter networks (e.g. STEMI networks in
Vienna, LINZ, Lower Austria South).
bBased on survey data in selected parts of the countries—see also Table 1.
S.D. Kristensen et al.1962
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increases in PPCI utilization were observed in 13 countries: Austria,
Bulgaria, Croatia, Greece, Italy, Latvia, the Netherlands, Portugal,
Romania, Serbia, Turkey, and England/Wales (Figure 1). Countries
like Denmark, France, and Sweden on the other hand experienced
a decline in PPCI procedures.
Utilization of thrombolysis
The use of thrombolysis was highest in Bosnia and Herzegovina,
Cyprus, Greece, and Serbia (Figure 2). The use was below 100 per
1 000 000 inhabitants in the majority of the countries.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Crude in-hospital mortality (%) of ST-elevation myocardial infarction (STEMI)
Country STEMI STEMI treated with PPCI STEMI treated with thrombolysis STEMI receiving no reperfusion
Bulgaria 12 6.1 11 19
Denmark 6 3.1 NA 11
Hungary 10 6 13.5 15.5
Iceland 5.5 NA NA NA
Italy 4 2.5 2.5 6.2
Macedonia 4.3 2.2 6.5 8.7
Portugal 6.7 3.3 NA 8.5
Poland 3.0 4.4 25 11.5
Romania 9.9 4.4 8.3 17.1
Spain 6.3 5 NA 13.4
Sweden 7.1 4.8 5.9 26
UK NA 4.4 NA NA
Based on data from countries with access to a national PCI and STEMI registry.
Figure 1 Primary percutaneous coronary interventions per 1 000 000 inhabitants in 37 ESC countries. Blue bars are data from 2007 and red bars
are data from 2010/2011.
Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011 1963
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Number of non-reperfused patients
The number of non-reperfused patients ranged from 19 to 526 per
1 000 000 inhabitants (Figure 3). A large number of countries were
unable to provide data on non-reperfusion.
Numbersofprimarypercutaneouscoronary
intervention centres and cardiologists
Table 2 summarizes the population of the countries, the number of
board-certified cardiologists, the number of PPCI performing
Figure 2 Thrombolysis per 1 000 000 inhabitants in 37 ESC countries 2010/2011.
Figure 3 No reperfusion therapy per 1 000 000 inhabitants in 37 ESC Countries 2010/2011.
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hospitals, the number of PPCI centres with a 24-h service 7 days a
week (24/7), and the mean number of the population served by a
24/7 service PPCI centre for each country in the year 2011.
The mean number of board-certified cardiologists ranged from 0.2
in Azerbaijan to 243.8 board-certified cardiologists per 1 000 000
inhabitants in Greece (Table 2). There was no significant correlation
between the number of cardiologists per 1 000 000 inhabitants and
the number of PPCI procedures (R ¼ 20.0013, P ¼ 0.99).
The mean population served by a single PPCI centre with 24/7
services (Table 2) ranged from 31 300 inhabitants per centre (San
Marino) to 6 533 000 inhabitants per centre (Saudi Arabia) (Table 2).
The number of PPCI capable centres with 24/7 services was highest
in Italy with 211 centres. In Cyprus, no PPCI centres existed at the
time of data collection.
Mortality
Table 3 displays the in-hospital mortality for STEMI patients overall
and the in-hospital mortality for STEMI patients treated with PPCI,
thrombolysis, and patients receiving no reperfusion therapy.
Overall in-hospital mortality in STEMI varied between 3% (Poland)
and 10.0% (Hungary), whereas mortality for patients treated with
PPCI was lower (range 2.2–6.1%). In countries with specific patient
identifiers that allow robust-confirmation of patient-specific mortal-
ity, the reported mortality in STEMI patients treated with PPCI was
3.1% (Denmark) and 4.8% (Sweden) (Table 3).
Discussion
The main finding in our descriptive study of reperfusion therapy in 37
ESC countries is that large national variation in treatment strategies
for patients admitted with STEMI still exists. Despite the fact that
international guidelines have been recommending PPCI as the first-
choice treatment for the last 10 years, this therapy is still not
implemented throughout ESC countries. Moreover, a substantial
number of patients are still not offered any reperfusion therapy.
However, due to the variety of data collection methods and registry
practices (Table 1), a direct comparison between countries should be
performed with caution.
Utilization of primary percutaneous
coronary intervention
Primary percutaneous coronary intervention as the first-choice trea-
tment strategy is well implemented in most Northern, Western, and
Central Europe countries, whereas the numbers of patients receiving
this therapy still are low in some of the Southern and Eastern coun-
tries. These findings relate closely to those in the first survey based
on data from 2007 published by Widimsky et al.4 Twenty-seven of
the 37 countries participated in this former survey. We found a
major increase in the overall numbers of performed PPCIs in 13 of
the countries compared with the data obtained in 2007. Especially
in the majority of the countries that are participating in the Stent
Figure4 Numbers of Primary Percutaneous Coronary Interventions per 1 000 000 inhabitants 2010/2011 in 37 ESC membercountries, grouped.
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for Life Initiative (Bulgaria, Greece, Italy, Portugal, Romania, Serbia,
Spain, and Turkey), an important increase was evident.3,9,10 More-
over, England/Wales reports a remarkable increase in the number
of patients treated with PPCI moving from ,40% of the STEMI
population treated with PPCI in 2006 to.90% in 2011.11 Countries
like Denmark, Sweden, and Switzerland experienced a significant
decline in PPCI utilization. On an explanation for this, evident in Den-
mark, would be the fact that the data from the survey in 2007/2008
were based primarily on an expert estimate, whereas that for the
present survey was based exclusively on national registry data.
Another plausible explanation is the decline in the incidence of
STEMI over the past years in some western countries, most likely
due to secondary better preventive treatments.12–14 Explaining vari-
ation in treatment utility and comparing levels across countries
remain a difficult task since it is highly influenced by multiple factors.
A gross estimate of 600 PPCI procedures per 1 million inhabitants
has served as the recommended treatment goal in the development
of a STEMI treatment strategy.15 The major barrier to this type of goal
setting is the lack of good nationwide registries that allow inter-
and cross-country comparisons at the patient level. The underlying
population demand is often unknown and such information will be
a prerequisite to address the full diversity of access to treatment
and to set specific treatment goals for individual countries. The
importance of considering differences in the need for PPCI is appar-
ent across Europe, where demographics vary highly and where death
rates from ischaemic heart disease (both sexes, all ages) are twice as
high in the UK as in Portugal.16,17 For example, in Ireland, the ratio of
elderly persons given as the number of .65 year old divided by the
number of persons ,65 is 17.2%, whereas in Italy this ratio is 30.9%
(2011, Eurostat, Population statistics).6,12,16 This stresses the need
for good quality data at the patient level with continuous monitoring
of incidence and treatment outcomes.6,12 Future studies could
benefit from reporting age standardized rates in order to make
data more comparable. Also, the underlying illness burden of the
population expressed as the level of co-morbidity (e.g. existing
diabetes and hypertension) may vary, and influence the demand for
PPCI. For example, in Saudi Arabia the percentage of people with
acute coronary syndrome (ACS) suffering from diabetes is as high
as 58% (2011),18 whereas the Danish Health and Medicines
Authority reports a prevalence among patients with ACS in
Denmark around 30%. However, most literature finds that supply
factors are the major drivers of implementation also for PPCI.19–22
Newer studies have found that the number of physicians is associated
with the level of PPCI utilization.21,22 In our study, we found no
correlation between the number of cardiologist and the number of
PPCI utilization.
However, previous studies have not only shown that regions that
spend more on health care on average have sicker patients, but also
that higher levels of illness explain only a fraction of the overall
difference in regional variations.23 –27 Another explanation for
the observed variations could be the countries reimbursement
schemes. Some studies have acknowledged the important influence
of payment methods on technology utilization.28,29 The reimburse-
ment schemes for both physicians and hospitals can be strong
incentives for treatment utilization and may explain some of the
observed variation in PPCI utilization. Moreover, the STEMI inci-
dence will be affected by the capability of early and correct diagnosis
of STEMI. Countries with newly established registries and STEMI
management strategies will most likely experience a rise in STEMI
prevalence and incidence for some years due to more patients
being diagnosed and registration improved. Clearly, there is a need
for a re-evaluation of the recommended level of PPCI usage adjusted
to the context of the country.
One other important factor that may, in part, account for the
observed differences in PPCI utilization is the definition of PPCI.
Some countries included procedures performed .12 h after sym-
ptom onset,21 and also some patients with non-STEMI or cardiac
arrest undergoing acute PCI. Furthermore, the data collection
methods varied substantially. Some countries did provide samples
or extrapolations of their STEMI total population, and thus, the
actual level of PPCI in the countries must be interpreted carefully.
For example, utilization rates for PPCI and thrombolysis (Figure 1
and 2) were considerable higher in Bulgaria than in Slovakia,
despite a similar level of acute myocardial infarction discharge rates
per 100 000 population (178.2 vs. 177.0, 2010, Eurostat, Health sta-
tistics).16 Moreover, in some countries, patients treated in private
hospitals may not have been included. Differences in registration
practice may therefore to some extent explain the reported differ-
ences (Table 1). However, we do not believe that differences in
data definition and data collection methods fully explain our findings
of a persisting large variation in reperfusion therapy.
Thrombolysis
Thrombolysis is still widely used in some Southern and Eastern coun-
tries, whereas countries like Denmark, Czech Republic, the Nether-
lands, and Sweden almost have stopped using thrombolysis in STEMI
patients. One plausible explanation for the existingwidespread use of
thrombolysis is that several countries do not have the required infra-
structure and timely access to catheterization laboratories with spe-
cialized personnel.9,30 In areas remote from PCI facilities where PPCI
cannot be delivered within the recommended time limit the benefit
of thrombolysis is well established and remains an important reper-
fusion strategy.1,31
Thrombolysis should preferably be administered in the pre-
hospital setting and should be followed by transfer to a PCI centre
as soon as possible for urgent (rescue) or subacute coronary angiog-
raphy.1,32 The optimal timing of routine angiography following suc-
cessful thrombolysis is not settled, but recent trials suggest a time
window of 2–12 h.1 Awell-organized system of carewith clear treat-
ment protocols and coordinated transfer systems is necessary for
identifying treatment-eligible patients for on-site thrombolysis or
transfer for PPCI, as treatment is highly dependent on time. Studies
have shown that system delay (time from first medical contact to ini-
tiation of reperfusion) is strongly associated with mortality, and the
risk of readmission to hospital with congestive heart failure.33– 36
As stated in the newly published STEMI guidelines from ESC, the
time from first medical contact to reperfusion with PPCI should
not exceed 120 min, and indeed, we should attempt to obtain even
shorter time delays.1
No reperfusion
STEMI patients who do not receive reperfusion therapy have a poor
outcome.37 Our survey demonstrates that a substantial proportion
of STEMI patients still are not receiving any reperfusion therapy
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(Figure 3), which highly stresses the need for actions to improve these
figures. Under-utilization of eligible STEMI patients is evident and
have been reported to compress 23–30%.38,39 The reported
numbers of non-reperfused patients in our study is hampered by
the fact that have very few registries on STEMI incidence exist
making it difficult to make valid estimates. Delays in admission to
the hospital, certain high-risk clinical features and substantial co-
morbidity have all been shown to be associated with lower utilization
rates of reperfusion therapy.38,39 Moreover, the definition of non-
reperfused patients may differ. For example, in Israel, the ACSIS
survey showed that 33% of the examined patients had spontaneous
reperfusion before reaching the catheterization laboratory and,
therefore, was registered as a non-reperfused patient. In other
studies, non-reperfused patients are the patients who are diagnosed
after .12 h of symptom onset. It has been suggested that achieving
late coronary patency in situations where patients present late
might still have beneficial outcomes with PPCI. However, this is still
debated.1,32 Getting patients to call for medical help as soon as pos-
sible after symptom onset is a challenge in many countries.9 There-
fore, efforts are highly needed to increase public knowledge on the
symptoms of myocardial infarction and of the awareness for immedi-
ate contact to the emergency medical system in order to shorten
patient delay.
Organization of reperfusion therapy
The number of PPCI capable centres with 24/7 service and the
number of cardiologists per 1 million inhabitants also varied consid-
erable between countries. Earlier studies, like the GRACE registry,
reported that the numbers of teaching hospitals and hospitals with
catheterization laboratories were indicators of a higher PPCI utiliza-
tion.40 A high use of PPCI most likely depends on the presence of the
necessary skills needed to perform the procedure and the availability
of appropriate facilities and equipment.41,42 Furthermore, it is pos-
sible that hospitals using PPCI have better resource allocation and
an organization that allow for better overall management of all
aspects of acute STEMI treatment, which most likely will lead to
better outcomes and reduced health-care system delay. The forma-
tion of STEMI networks involving emergency medical services,
non-PCI hospitals, and PPCI centres could be necessary to imple-
ment PPCI services effectively.1,32,43 Besides single tertiary centres
serving a specific area for 24 h, some countries and regions have
developed rotational systems of STEMI care, in which three and up
to five interventional cardiology centres share the PPCI function
during night time. These systems have shown to be cost-effective
with comparable lowmortality rates as single tertiary centresoffering
24/7 services, and at the same time guarantees that only experienced
interventionalists are on duty.44 Most importantly, these STEMI net-
works have been shown to reduce the number of non-reperfused
patients. The population served by a centre must be sufficient to
maintain the competency of the centre. However, setting meaningful
thresholds for minimum numbers of PPCI per year to maintain the
competency of both the hospital and the operator is difficult and
still remains a question for future research and discussion.45,46
Mortality
In-hospital mortality for STEMI patients treated with PPCI varied
between 3.1 and 6.1%. The reported in-hospital mortalities are
consistent with evidence from other observational studies.2,3,47,48
However, comparison of in-hospital mortality across populations is
fraught with problems. Mortality data are highly dependent on the
population studied and the methodologies for data collection and
coding. For example, the overall mortality in patients with cardiogenic
shock (usually 8–10% of patients in STEMI networks) is 40–50%, and
the numberof these patients will influence the mortality rate positively
or negatively depending on their inclusion or absence in the registries.
In well-organized networks, the in-hospital and 30-day mortality
ranges from 3 to 5%.43 The newly published FAST-MI trial from
France reported a decrease in 30-day mortality from 13.7 to 4.4% in
the period 1995 to 2010.3 Moreover, they noted that overall mortality
decreased irrespective of use and the type of reperfusion therapy,
including the patients who did not receive any reperfusion therapy,3
indicating that other factors such as better preventive drug therapy
and changes in lifestyle are important.
Why is primary percutaneous coronary
intervention not implemented?
The variation in uptake of PPCI appears to be present worldwide,
and is not explained solely by economic incentives, illness severity,
or patient preferences. The scant evidence within the field indicates
that the barriers for PPCI implementation are a complex mix of
medical, organizational, patient-related, regulatory, and economic
factors.6,21 Many factors still need to be addressed in order to under-
stand and explain the remaining large variation in treatment utiliza-
tion across Europe. The Stent for Life Initiative is, in our opinion, a
good example of a joint multi-level effort identifying barriers at a
national and regional level in order to change practice, and would
be an example for other countries to follow.
Strength and limitations
The major strength of the study is that we were able to include a large
numberof countries that provided up-to-date information on the use
of reperfusion therapy. STEMI is a common and well-defined clinical
condition worldwide, allowing international comparison. Moreover,
we provide updated information on the number of hospitals with
PPCI facilities and the number of cardiologists for each country.
The major limitation of our study is the quality of the data, and
several points should be highlighted. First, discrepancies in the way
the data were collected; the coding of STEMI and in the definition
of PPCI in the 37 countries are clearly hampering our study and
may lead to both under- and overestimation of the actual reperfusion
utilization and thus make cross-country comparisons difficult. Sec-
ondly, only a minority of the countries have mandatory registries,
and outcomes are not based on an exhaustive collection of the
STEMI population in the whole country. Moreover, the majority of
countriesparticipation in the surveychangedorexpandedtheir regis-
tration since the previous survey conducted in 2007/2008, which
even makes within country comparisons difficult. Incomplete or non-
compulsory reporting from hospitals may bias the factual size of the
reported inequality, but the size and direction of the bias is unknown.
Furthermore, data in four countries were based on best expert esti-
mates and extrapolations, which most likely will lead to an overesti-
mationof the actual use.Countries notparticipating in the survey may
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be countries with less-developed STEMI programmes. This would
underestimate the actual level of variation across Europe. The
survey makes it possible for countries to highlight their problems
regarding PPCI implementation. Mortality data are highly affected
by the underlying population, e.g. the percentage of patients with
out-of-hospital cardiac arrest and shock. Unfortunately, our study
wasbasedonaggregatedcountry-leveldatawithnoaccess todetailed
patient-level data. Thus, comparison of mortality data across coun-
tries should be done with caution.
Since STEMI incidence in most countries is unknown, we choose
to present reperfusion therapies as the numbers of patients treated
with the different modalities per million inhabitants instead of
percentage. It can be argued that this is a crude instrument especially
when populations are diverse. However, we feel that this is the
most valid estimation we could obtain.
While these findings must be interpreted with caution given the
limitations of the study, and the difficulties with cross-country com-
parisons, this mapping of the current status of reperfusion therapy
across a large number of European countries is nevertheless instruct-
ive in presenting a picture of a striking international variation in the
treatment strategies in patients admitted with STEMI.
Conclusions and future
perspectives
In conclusion, our study demonstrates striking differences in the man-
agement of patients admitted with STEMI in 37 ESC countries. It
seems that a significant deviation from the guideline recommenda-
tions is still prevailing, and an understanding of the reasons behind
under-utilization of reperfusion therapy is a prerequisite for reducing
or eliminating such gaps in healthcare.
In an attempt to reduce differences in a number of European coun-
tries, the Stent for Life Initiative, supporting the implementation of
timely PPCI was established in 2008.15,49 The participating countries
already report striking rises in PPCI utilization, reduction in mortality,
and an overall more effective management/organization of the STEMI
treatment system, which strongly calls for a continuation of a strategy
of implementation and supports of countries with low activities.9,49
A major challenge for improvement of the care and outcome of
STEMI patients in Europe is the lack of accurate and comprehensive
data. The availability of complete reperfusion data and patient
outcome is a prerequisite to address the full diversity of access to
treatment in order to improve treatment availability and outcomes
for STEMI patients in the future. Systematic use of large data-based
registries on STEMI treatment is highly needed. Also, the establish-
ment of key indicators underpinned by key items of data with data
definitions and clear analytical steps as used in other organizations
might be helpful.
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Papillary fibroelastoma of the mitral valve as an unusual cause of myocardial
infarction in a 20-year-old patient
Katarzyna Piestrzeniewicz, Katarzyna Łuczak, Piotr Jakubowski*, Piotr Kula, Ryszard Jaszewski,
and Jarosław Droz˙dz˙
Department of Cardiology and Cardiosurgery, Medical University of Lodz, Lodz, Poland
* Corresponding author. Tel: +48 693419457, Fax: +48 426364471, Email: pbjakubowski@wp.pl
The incidence of primary cardiac tumours is ,0.1% and
papillary fibroelastomas are relatively rare when com-
pared with myxomas and lipomas. Papillary fibroelastoma
is generally small and single, occurs most often on valvular
surfaces, andmaybe mobile.Despite the embolic potential
of primary cardiac tumours, they are extremely uncom-
mon cause of ischaemic vascular accidents. Patients with
smaller tumours, situated on the aortic valve and in the
left atrium, with minimal symptomatology and no evidence
of mitral regurgitation have a higher risk of embolism.
Several causes of myocardial infarction in young patients,
mostly non-atheromatous origin, have been described.
These are congenital coronary artery anomalies, aneur-
ysms, spontaneous dissection, myocardial bridging, septic
coronary emboli or bacteraemia, and paradoxical embol-
ization through a patent foramen ovale. Only a few cases
of acute coronary syndrome caused by papillary fibroeles-
toma were reported.
A 20-year-old male patient with no cardiovascular risk
factors, with a history of recurrent pre-syncope was admit-
ted tothehospitalwithST-segmentelevationmyocardial in-
farction. An amputation of the left descending coronary
arterywas revealedanda thrombus-likemass was removed.
A following transthoracic echocardiogram showed abnormal contraction of the apex and interventricular septum and a round, hyper-
echoic, well-demarcated, homogenous, non-mobile tumour of 5 mm in diameter attached to the atrial side of mitral annulus, with no
influence on valvular function. Transoesophageal echocardiography revealed no other masses in the heart chambers or great arteries
and no patent foramen ovale. Surgical excision of the tumour was successfully performed 4 weeks after myocardial infarction and post-
operative course was uncomplicated. The histological examination revealed papillary fibroelastoma.
We believe that in young patient with acute coronary syndrome echocardiography should be performed prior to initiating reperfusion
therapy.
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